Corgenix to Exhibit AspirinWorks(R) Test at AHA 2007 Meeting in Orlando
Thursday October 25, 9:00 am ET
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCBB: CONX - News), a worldwide developer and marketer of diagnostic test kits, has announced it will be exhibiting its new AspirinWorks® Test Kit at the American Heart Association Scientific Sessions 2007. The annual meeting takes place November 4 - 7 at the Orange County Convention Center in Orlando, FL.
The test measures the effect of aspirin on platelets through direct measurement of thromboxane production (aspirin’s target). The stickier the blood platelets, the less impact the aspirin is having. This crucial information allows physicians to individualize a patient’s therapy.
The AspirinWorks test was launched in the United States in June 2007 following FDA 510(k) clearance, and it is now available nationwide through major medical reference laboratories as well as direct to consumers through HealthCheckUSA (www.HealthCheckUSA.com).
Unlike other platelet tests, which require freshly drawn blood that must be evaluated within at least 4 hours, the AspirinWorks test only requires a urine sample that can be obtained in any doctor’s office or patient service center, making the test easy for both physician and patient.
“This AHA conference represents an excellent setting to educate the physician community about the new test,” said Corgenix’ Clinical Affairs Director Gordon Ens. “With AspirinWorks widely available, physicians now have more information to determine if the patient’s current dose of aspirin is demonstrating an effect. That’s the value of the results the AspirinWorks product provides.”
Corgenix representatives will be on-hand during the AHA conference in booth #1002 to answer questions about Corgenix’ full line of diagnostic tests as well as AspirinWorks, including availability of the test, the latest supporting clinical data and how to order the test.
The AspirinWorks Test Kit is an enzyme-linked immunoassay (ELISA) to determine levels of 11 Dehydro Thromboxane B2 (11dhTxB2) in human urine, which aids in the qualitative detection of aspirin effect in apparently healthy individuals post ingestion. The test targets a potential U.S. market of over 60 million individuals and a potential global market exceeding 200 million individuals who take aspirin regularly.
Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or e-mail: info@aspirinworks.com. More information is also available at www.aspirinworks.com.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.
Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe,” “estimate,” “project,” “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
Contact:
Corgenix Medical Corp.
William Critchfield, 303-453-8903
Senior VP and CFO
wcritchfield@corgenix.com
or
Armada Medical Marketing
Dan Snyders, 303-623-1190, ext. 230
Vice President, Public Relations Supervisor
dan@armadamedical.com
Source: Corgenix Medical Corporation |
